Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 69

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 69
---
 rights plan in effect. If the ordinary shares cease to be represented by American Depositary Shares issued under a depositary receipt program sponsored by us, each reference herein to the ADSs related to the terms of the notes will be deemed to have been replaced by a reference to the number of ordinary shares and other property, if any, represented by the ADSs on the last day on which the ADSs represented the ordinary shares and as if such ordinary shares and other property had been distributed to holders of the ADSs on that day. In addition, all references to the “last reported sale price” of the ADSs will be deemed to refer to the “last reported sale price” of the ordinary shares, and other appropriate adjustments, including adjustments to the conversion rate, will be made to reflect such change. In making such adjustments, where currency translations between U.S. dollars and any other currency are required, the exchange rate in effect on the date of determination will apply. Notwithstanding any of the foregoing, the conversion rate will not be adjusted:

| • | upon the issuance of any ordinary shares (multiplied bythe number of ordinary shares then represented by one ADS) or ADSs at a price below the conversion price or otherwise, other than any such issuance described in clause (1), (2) or (3) above; |

| • | upon the issuance of any ordinary shares or ADSs pursuant to any present or future plan providing for the reinvestment of dividends or interest payable on our securities and the investment of additional optional amounts in ordinary shares or ADSs under any plan; |

| • | upon the issuance of any ordinary shares or ADSs, or options or rights to purchase those ordinary shares or ADSs pursuant to any present or future employee, director or consultant benefit or incentive plan or program (including pursuant to any evergreen plan) of or assumed by us or any of our subsidiaries; |

| • | upon the issuance of any ordinary shares or ADSs pursuant to any option, warrant, right or exercisable, exchangeable or convertible security not described in the preceding bullet and outstanding as of the date the notes were first issued; |

S-39

TABLE OF CONTENTS

| • | for a third-party tender offer by any party other than a tender offer by one or more of our subsidiaries as described in clause (5) above; |

| • | upon the repurchase of any ordinary shares or ADSs (and the ordinary shares represented thereby) pursuant to an open market share purchase program or other buy-back transaction, including